MedPath

The Value of Diffusion-weighted Imaging in Evaluating the Early Efficacy of Liver Metastasis in Colorectal Cancer

Not Applicable
Conditions
DWI-MRI
Interventions
Device: Diffusion weighted magnetic resonance imaging
Registration Number
NCT03088163
Lead Sponsor
Fudan University
Brief Summary

The study is designed to evaluate the value of DWI-MRI (Diffusion weighted magnetic resonance imaging) in predicting the efficacy of liver metastases after chemotherapy in colorectal cancer.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
100
Inclusion Criteria
  • aged ≥18 years with histologically or cytologically confirmed advanced colorectal adenocarcinoma
  • Eastern Cooperative Oncology Group performance status of 0 to 2
  • life expectancy of ≥ 3 months
  • at least one measurable liver metastatic lesion in MRI (≥10mm)
  • have adequate bone marrow, hepatic, and renal function
  • previously received no palliative chemotherapy
Exclusion Criteria
  • patients with previous chronic inflammatory bowel disease, chronic diarrhea or recurrent bowel obstruction
  • patients with symptomatic brain metastases
  • active clinical severe infection
  • have contraindication of MRI screening

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
DWI-MRIDiffusion weighted magnetic resonance imaging-
Primary Outcome Measures
NameTimeMethod
Response rate2 months

the response rate predicted by DWI-MRI

Secondary Outcome Measures
NameTimeMethod
Progression free survival2 months
Overall survival2 months

Trial Locations

Locations (1)

Fudan University Cancer Hospital

🇨🇳

ShangHai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath